NASDAQ:ARQT 30 December 2025

Arcutis Biotherapeutics stock slides after 2026 ZORYVE sales outlook; June FDA deadline in focus

Shares of Arcutis Biotherapeutics dropped 8.7% on Monday, slipping $2.46 to $25.76, following the company’s update on its 2026 priorities. The dermatology drugmaker set a $455 million to $470 million target for net product sales in its ZORYVE franchise. The stock hit a session low of $25.51 during trading.

12 January 2026

NASDAQ:ARQT·Pharmaceuticals·Stock Market

Arcutis stock sinks 5% after wild swing as traders eye Fed, FDA clock and earnings

Arcutis Biotherapeutics shares slid 5.3% to $28.29 in afternoon trading on Friday, after climbing as high as $30.70 earlier. The stock was last at the session low.

9 January 2026

Earnings Reports·Federal Reserve·NASDAQ:ARQT·Stock Market

Arcutis Biotherapeutics stock today: ARQT ends 2025 up 3.4% as traders eye FDA, earnings dates

With U.S. markets closed for New Year’s Day, shares of Arcutis Biotherapeutics Inc last closed up 3.42% at $29.04 in the final trading session of 2025. The stock ranged from $28.08 to $29.67 on volume of about 1.87 million shares. ARQT is up about 99% over the past year and has traded between $11.13 and $31.77 over the last 52 weeks. Investing.com

2 January 2026

Earnings Reports·NASDAQ:ARQT·Stock Market

Arcutis stock (ARQT) in focus after insider sale notice as U.S. markets shut for New Year’s Day

Arcutis Biotherapeutics shares are in focus after a regulatory filing showed an executive planned to sell a small block of stock, with U.S. markets closed on Thursday for New Year’s Day. The dermatology drugmaker last closed up 3.4% at $29.04 on Dec. 31. Intercontinental Exchange

1 January 2026

NASDAQ:ARQT·Stock Market

Arcutis Biotherapeutics stock pops today as ARQT bucks biotech dip into year-end trade

Shares of Arcutis Biotherapeutics Inc rose 3.8% to $29.16 by 10:33 a.m. ET on Wednesday, extending gains in the final U.S. trading session of 2025. The Nasdaq-listed dermatology drugmaker traded between $28.08 and $29.19, with about 181,000 shares changing hands.

31 December 2025

NASDAQ:ARQT·Pharmaceuticals·Stock Market

Arcutis Biotherapeutics stock slides today as biotech pulls back, ARQT down nearly 3%

Arcutis Biotherapeutics shares fell 2.9% to $27.74 in afternoon trading on Tuesday, after moving between $27.72 and $28.65. Volume was about 0.6 million shares.

30 December 2025